Effect of low radiation dose on cisplatin induced hepatotesticular damage in male rats.

- 3
- 4

5 ABSTRACT

Aim: The aim of this study was to evaluate the synergistic effect of low radiation dose with the chemotherapeutic drug in order to find possible way to lessen the harmful effects during chemo-radiotherapy.

Study Design: Randomized controlled experiment.

Place and Duration of Study: Experimental Animal Unit, Drug Radiation Research Department, National Center for Radiation Research and Technology, Cairo Egypt.

Methodology: Estimation of antioxidant activity of low radiation dose on oxidative stress induced by cisplatin administration at a dose of 10 mg/kg b. wt. in male albino rat.

Results: Results of experiment revealed that cisplatin administration caused a significant increase in serum alanine transaminase (GPT) activity (38.58 ± 2.060) and FSH level (8.162 ± 1.424) accompanied with a decrease in serum albumin (3.492 ± 0.253), and Butyry Cholein Esterase (BChE) (65.3512.61). In Liver and testis, GSH content ($68.00\pm2.391\&24.93\pm4.778$) as well as cytochromes P450 levels ($0.3875\pm0.0727\&0.2167\pm0.0459$) showed a significant decrease as compared to the normal control level respectively. In addition the level of Fe, Cu and Zn showed no significant changes in liver and appeared to be significantly decrease as in case of corresponding trace elements in testis organs. On the other hand, exposing to low dose of radiation (0.5 Gy) post-cisplatin treatment effectively prevented these alterations and maintained the antioxidant status.

Conclusion: Data from present results revealed that low radiation dose have the existence as an antioxidant and antitumor agents which may be useful to use as a synergistic agents with the chemotherapeutic drug.

6

7 Keywords: Low Radiation Dose, Cisplatin, Cytochromes P450, Butyryl Cholein Esterase.

8 1. INTRODUCTION

9 Cisplatin is one of the most potent anticancer drugs used in chemotherapy. It is highly effective in the treatment of 10 testicular and ovarian cancers as well as bladder, cervical, head and neck, esophageal and small cell lung cancer [1]. Despite being an effective anti-proliferative agent, the clinical usage of cisplatin is limited by various side effects including 11 12 nephro-toxicity, hepato-toxicity, neurotoxicity and oto-toxicity. The anticancer activity of this drug is attributed to its 13 capacity to form covalent bond at N-7 position of Guanine residues of DNA leading to formation of 1, 2 or 1, 3 inter-strand 14 crosslink and a lesser extent of the inter-strand crosslink (Fig. 1). This adduct cisplatin DNA disrupts the cellular 15 replication and transcription machinery [2]. Many labs have demonstrated that cisplatin generates free radicals leading to oxidative and nitrosative stress which results into such deleterious effects in vivo [3, 4]. It is generally accepted that 16 17 binding of cisplatin to genomic DNA (gDNA) in the cell nucleus is the main event that responsible for its antitumor 18 properties [5]. Thus, the damage induced upon binding of cisplatin to gDNA may inhibit transcription, and/or DNA 19 replication mechanisms. Subsequently, these alterations in DNA processing would trigger cytotoxic processes that lead 20 to cancer cell death. The cytotoxicity of cisplatin is considered to be due to combination factors, including peroxidation of 21 cell membrane, mitochondrial dysfunction, inhibition of protein synthesis, and DNA injury [6].

22 Till the last decade of the last century, radiotherapy was considered to be the only therapeutic option for patients with 23 locally advanced cancer [7]. There were some trails of combined cisplatin and radiation therapies have been reported 24 and it has proved to be hopeful method to improve the treatment results of invasive bladder cancer [8]. The effectiveness 25 of the combination of cisplatin and radiation in experimental malignant tumor was reported by Wodinsky and his 26 colleagues [9] in leukemic cell. Morris and his colleagues noted a similar effect in mouse leukemia [10]. Cyto-toxic 27 chemotherapy has been shown to give good response rates in patients with good kidney function and no prior radiation 28 therapy. Cisplatin is the most effective single agent [11] and it was shown to be synergistic with radiotherapy in cell lines. 29 Mechanisms underlying the interaction between drugs and radiation may include inhibition of potentially lethal or sub-30 lethal damage repair, and increasing radio-sensitivity of hypoxic cells [12]. It has been widely used prior to surgery or 31 radiotherapy with the aim of reducing tumor volume and facilitating local treatment. It may have the additional benefit of

32 controlling micro-metastatic disease. Combined chemo-radiotherapy seems to offer substantial benefit for women with 33 cervical cancer. However, acute toxicity, predominantly hematological and gastrointestinal, was increased with chemo-34 radiation [13]. Acute side effects are generally of short duration and resolve with medical management, while the late 35 complications of radiotherapy lead to damage which can be difficult to reverse, and permanently impair quality of life. 36 Details of late morbidity are more poorly documented, but with the exception of one trial [14].




Fig. (1) Main adducts formed after binding of cisplatin to DNA.

(A) 1,2-intrastrand cross-link, (B) interstrand cross-link,
(C) mono- functional adduct, and (D) protein-DNA cross-link. The main site of attack of cisplatin to DNA (N7 of guanine) is shown in the central panel [2].

49 Low dose of radiation induce various effects including radio-protective response [15], as well as activation of immune 50 function [16]. It has been well documented that the immune function is linked to the release of radical oxygen species 51 (ROS). Access amount of ROS is commonly eliminated by endogenous antioxidant system, thereby preventing injury to 52 DNA [17]. It exerts protection against other challenges involving radicals and causing a beneficial effect by temporarily 53 shielding the hit cell against radicals produced through endogenous processes. Low dose of radiation has been observed 54 to stimulate the radical detoxification system, enhancement of DNA repair rates and induce immune competence that 55 associate with an increase in number of cytotoxic lymphocytes, even causing a reduction of the incidence of metastatic 56 cancer [18]. Our pervious study indicated that treatment with low dose of gamma rays (0.5 Gy) ameliorate harmful effects 57 induced by TCE due to the effect of gamma radiation as a stimulant of radical detoxification [19].

According to many clinical studies, when chemotherapy and radiotherapy are concurrently administered improve effectively greater rather than at different times [20]. Combined chemo-radiotherapy presents some problems; however, with more sever adverse events, resulting in a reduced treatment compilation rate [21]. On the other hand, according to the study of Murphy and Morton [22] and Barcellos-Hoff, [23], low radiation dose administartion to entire body increased the action of the protective process in living organism including the overproduction lymphocytes that significantly prevented or impaired tumor growth. From this point of view, the current study's aim is to investigate the synergistic effect of low radiation dose in the treatment with cisplatin as a chemotherapeutic drug inducing oxidative stress.

65 2. MATERIAL AND METHODS

66 **2.1. Animals**

67 Male albino rats weighing approximately 120-150 g were used for this experiment. They were housed in polypropylene 68 cages in an air conditioned room with temperature maintained at 25 °C \pm 3 °C, relative humidity of 50 % \pm 5 % and 12 h 69 alternating light and dark cycles. The rats were provided with a nutritionally adequate chow diet and drinking water *ad* 70 *libitum* throughout the study. Experiments were begun after a four-week acclimatization period.

71 72

2.2. Chemicals

Cisplatin was purchased from Central Drug House (Egypt). The chemicals used in this experiment were obtained from
 Sigma Chemical (USA). Kits used in this experiments were purchased from Bio-Diagnostics (UK).

75 **2.3. Radiation process:**

A single dose whole body irradiation (0.5 Gy) was performed with rats, using gamma rays by Cesium 137 irradiation unit, National Center for Radiation Research and Technology (NCRRT), with the dose rate 0.74589 rad/ sec. The gamma cesium cell was calibrated by alanine dosimetry relative to a primary standard. Correction were made daily for humidity, temperature, and barometric pressure.

81 2.4. Experimental design

82 Adult male albino rats were divided into 4 groups of 6 rats each and treated as follows:

83 Control group (normal, untreated), received distilled water. Cis. group, received freshly dissolved cisplatin in 1 ml 84 distilled water at a dose of 10 mg/ kg body weight (I.P); IRR group was exposed to a single low gamma radiation dose of 85 0.5 Gy and Cis. & IRR group was administered with Cisplatin, 24 hr after cisplatin administration the animals were 86 exposed to a single low dose of gamma rays (0.5 Gy). The dose of cisplatin was decided on the basis of Máthé and his 87 colleagues [24]. Twenty four hours after radiation exposure the animals were decapitated and the blood was collected for 88 biochemical analysis. Liver and testes were divided into two portions. One portion were excised, homogenized in ice-cold 89 saline and utilized for various biochemical analyses and the second portion was used for trace elements analysis.

90 2.5. Biochemical analysis

91 The blood samples were collected directly from the animals by heart puncturing. They were centrifuged at 3000 rpm for 92 15 min., clear sera were collected and stored in a refrigerator. The activities of GPT, BChE and FSH levels as well as 93 concentrations of albumin in serum were analyzed. Liver and testis were minced and homogenized (10 % w/ v) in ice-94 cold normal saline solution. The homogenate was centrifuged at 3,000 rpm for 15-20 min at 4 °C. The resultant 95 supernatant was used for estimation of GSH content and cytochrome P450 activity. Serum BChE activity is quantitatively 96 measured according to the methods published in Munshaw and his colleagues [25]. FSH level was detected in serum 97 samples using elisa kit supplied by (Kamiya, biomedical company, USA) according to manufacturer instruction. The elisa 98 kit was read using 2100 elisa reader. Serum albumin level was determined according to the method of Doumas and his 99 colleagues [26]. In addition GSH content in both liver and testis was measured by method of Beutler and his colleagues 100 [27]. Liver and testis cytochrome P450 activity assayed was detected using a spectrofluorometer [28]. Serum BChE and 101 FSH activities as well as liver and testis P450 were carried out at the Central Laboratory, Radioisotope Dept., AEA, Giza, 102 Egypt, while serum GPT activity and Albumin concentration, as well as tissue GSH content were performed with a Helios 103 Thermo-Spectronic spectrophotometer (Thermo Spectronic, UK).

104 2.6. Atomic absorption analysis

105 Liver and testes tissues were digested in a mixture of conc. HNO₃ and H₂O₂ (5:1). The digestion was completely by using 106 miocro-wave oven (mls- 1200 mega) and the digested samples were diluted with de-ionized water to a fixed volume [29]. 107 The selected element was estimated quantitatively by atomic absorption spectrophotometer. Unicam 939 Hallow cathode 108 lamps were used to determine Fe, Cu and Zn in air acetylene flame [30]. Concentration of elements in tissues was 109 calculated by using calibration curve prepared from their stock solution (1mg). The concentration of elements per grams 110 tissues could be determined by equation: 111

Elemental content in the tissue $(\mu g/g) = c \cdot v \cdot n / m$,

112 Where: c (µg/ml) is the concentration of the metal measured in the AAS sample of volume v (ml), n is the dilution factor 113 and m (g) is the mass of the tissue taken. Wet tissue weights were used for calculating the metal concentration in tissues 114 [31].

2.7. Statistical analysis:


117 To assess the significant level of influence caused by low dose of radiation in cisplatin administrated rats, one way 118 analysis of variances (ANOVA) followed by Tukey's multiple comparison test was used. Data are representative of 6 119 independent experiments carried out in triplicate. Statistical analysis was performed by using Graph-Pad software, San 120 Diago, CA, USA) Differences were considered statistically significant when the P value was less than 0.05. 121

3. RESULTS

122 123

115 116

124 Cisplatin is one of the most potent anticancer drugs used for the treatment of different types of cancer including testicular 125 cancer. In spite of its significant anticancer activity, the clinical use of cisplatin is often limited by its undesirable side 126 effect due to the influence of oxidative stress. Results indicated in fig. (2) in addition to table (1-4) evaluate the effect of 127 cisplatin and the synergistic effect of low irradiation dose (0.5 Gy) on liver and testis tissues.



■ Control group ■ Cis group ■ IRR group ■ Cis+IRR group



Fig. 2: Effects of cisplatin administration and/ or radiation exposure on some serum biochemical parameters 24 hours post radiation exposure (n=6)

131 132 133

129

130

Data are presented as mean (± SD). * Significantly different from the control group (P<0.05). (#) Significantly different from the Cis. group (P<0.05). IRR: Low radiation dose of 0.5 Gy gamma rays, Cis group: cisplatin administration.

134 3.1. Cisplatin demonstrated toxicity in both liver and testis:

135 Cisplatin induced liver damage: 3.1.1.

136 Cisplatin administration caused a significant decrease in serum albumin concentration as well as BChE activity which 137 recorded -12.9% and -25.6% (P<0.05) as compared to the normal control level. This decrease in serum albumin and 138 BChE levels accompanied with a significant increase in serum GPT activity which calculated 35% comparing to the 139 corresponding control group Fig. (2).

140 On the other hand, administration of cisplatin caused a significant decrease in both liver GSH (-13.9%) and P450 (-141 26.9%) concentration (P<0.05) as compared to the normal control level. Table (1).

142 The effect of cisplatin injection on liver trace metals is shown in table (3). Administration of cisplatin caused no significant 143 change on liver Fe, Zn as well as Cu concentration when these data were compared to the normal untreated control 144 level.

145 146

Table 1: Effects of cisplatin administration and/ or radiation exposure on liver GSH and0cvtochrome P450. 24 hours post radiation exposure (n=6)

	Treatment X ⁻ ± SD	Control group	Cis group	IRR group	Cis & IRR group	
_	GSH (mg/g tissue) X ⁻ ± SD	78.94 ± 2.4	68.00 ± 2.4*	86.53 ± 2.7 ^{*(#)}	76.00 ± 7.6 ^(#)	
	Cytochrom P450 (pmole/ml/min) X ⁻ ± SD	0.5300 ±0.034	$0.3875 \pm 0.073^{\circ}$	0.6025 ±0.061	0.4825 ± 0.059 ^(#)	

147 Data are presented as mean (± SD). *Significantly different from the control group (P<0.05). (#) Significantly different from the Cis. 148 group (P<0.05). IRR: Low radiation dose of 0.5 Gy gamma rays, Cis: cisplatin administration.

3.1.2. 149 Testicular toxicity due to cisplatin administration:

150 Testicular toxicity was detected by measuring the activity of FSH hormones in serum. Serum FSH showed a significant

151 increase due to the injection of cisplatin (10mg/kg b.wt I.P), the percentage increase in serum FSH was calculated 78%,

152 (P<0.05) when compared to the normal control level (Fig. 2). Administration of cisplatin (10mg/kg b.wt I.P) to the animal brought about a marked reduction in both GSH content and P450 concentration in testis tissue that recorded -23%, (*P*<0.05) and -48% (*P*<0.05) as compared to the control level respectively (Table, 2).

Table (4) displays the effect of cisplatin administration on certain trace elements concentration, which indicated a significant decrease in testis Fe, Zn and Cu levels. The percentage decrease of these elements was nearly the same (-29%, -29% and -22.4%, *P*<0.05) comparing to the normal untreated control respectively.

159 160

 Table 2: Effects of cisplatin administration and/ or radiation exposure on testis GSH and cytochrome P450, 24 hours post radiation exposure (n=6)

Treatment X ⁻ ± SD	Control group	Cis group	IRR group	Cis & IRR group
GSH (mg/g tissue) X⁻ ± SD	32.36 ± 2.6	24.93 ± 4.8*	39.30 ± 4.2*(#)	35.38 ± 3.1 ^(#)
Cytochrom P450 (pmole/ml/min) X ⁻ ± SD	0.4160 ± 0.043	0.2167 ± 0.046*	0.3780 ± 0.05 ^(#)	0.4027 ± 0.046 ^(#)

 161
 Data are presented as mean (± SD). *Significantly different from the control group (P<0.05). (#)Significantly different from the Cis.</td>

 162
 group (P<0.05). IRR: Low radiation dose of 0.5 Gy gamma rays, Cis: cisplatin administration.</td>

163 **3.2.** Low dose of radiation exposure showed no significant change in both liver and testis:

164 **3.2.1.** Low dose of radiation (0.5 Gy) induced no change in liver function:

Exposing animals to low dose of radiation (0.5 Gy) caused no significant change in the concentration of serum albumin as well as the activities of GPT and BChE as compared to the normal control level (Fig. 2). Moreover, a significant increase was shown in the level of serum albumin and BChE recording 13% and 36% (*P*<0.05) comparing to the cisplatin treated group.

169 On the other hand, 0.5Gy dose of whole body gamma radiation detected a significant increase in liver GSH content 170 comparing to the normal control level. This increase was calculated 9.6% and 27% as compared to both control and 171 cisplatin treated group respectively (Table 1), while liver P450 concentration showed no significant change comparing to 172 normal control levels accompanied by a significant increase (74%, *P*<0.05) in respect to cisplatin treated group.

Finally table (3) showed a non significant change in all tested trace element as compared to both control and cisplatintreated groups.

175 **3.2.2.** Testicular state after low dose of gamma radiation (0.5 Gy):

Exposing animals to low dose of radiation (0.5 Gy) caused no significant changes in serum FSH level as regard with
 normal control level (Fig. 1). Comparing this group with cisplatin treated one detected a significant increase by 56.5%
 (*P*<0.05) in serum FSH level (fig. 2).

179 In table (2) the effect of low dose of radiation showed a significant increase in testis GSH content in respect to both 180 control untreated and cisplatin treated groups. The percentage of this increase calculated 21.44% and 57.6% (*P*<0.05) 181 respectively. In addition, non-significant increase was evaluated in P450 concentration due to exposing animals to low 182 dose of radiation with a significant increase when P450 level compared with cisplatin treated group (74%, *P*<0.05) table 183 (2).

184 In case of trace metals concentration, testis Fe, Zn as well as Cu concentration was estimated in the group of animals 185 exposed to the low dose of gamma radiation (0.5 Gy). Table (4) showed a non significant change on the level of Fe, Zn and Cu in low dose of radiation exposure group when these data compared to the normal untreated control level.

187

188

190 Table 3: Effects of cisplatin administration and/ or radiation exposure on levels of Fe, Zn and Cu in liver tissue 24 hours post radiation ovnocuro (n-6)

exposure (<i>n</i> =6)					
Treatment X [.] ± SD	Control group	Cis. Group	IRR group	Cis. & IRR group	
Fe (µg/g fresh tissue) X⁻ ± SD	205.6±35	183.1±15	186.8±17.8	190.2±21.7	
Zn (µg/g fresh tissue) X⁻ ± SD	119.7±16.3	112.9±13.5	98.86±13.2	102.3±19.9	
Cu (µg/g fresh tissue) X⁻ ± SD	3.450 ± 0.49	3.308 ±0.27	3.322 ± 0.3	3.087 ± 0.28	

192 Data are presented as mean (± SD). *Significantly different from the control group (P<0.05). (#)Significantly different from the Cis. 193 group (P<0.05). IRR: Low radiation dose of 0.5 Gy gamma rays, Cis: cisplatin administration.

194

3.3. The synergistic effect of low dose of radiation exposure with cisplatin administration in both liver and 195 testis:

196 3.3.1. Low dose of radiation (0.5 Gy) induced a significant amelioration in liver function:

197 Fig. (2) showed a full restoration in serum albumin concentration as well as GPT and BChE activities in animals group 198 exposed to low dose (0.5 Gy) gamma radiation after cisplatin treatment as regarded to the normal control value. Besides, 199 a significant increase in both serum albumin and BChE levels was recorded 13% and 20% (P<0.05) as compared to the 200 cisplatin treated group respectively. However, serum GPT activity in the previous group showed no significant increase 201 when compared with cisplatin treated one.

202 According to data in table (2) the effect of low dose of gamma rays (0.5 Gy) showed a full amelioration as in case of both 203 liver GSH and P450 concentration and their levels become more or less as the normal untreated control level. Comparing 204 liver GSH and P450 concentration results in animals group treated with cisplatin before exposing to gamma rays together 205 with cisplatin treated one showed a significant increase calculated 11.8% and 24.5% (P<0.05) as in table (2).

206 Table (4) showed the effect of low dose of radiation after cisplatin administration in all tested trace metals concentration 207 that indicated a non significant change in liver Fe, Zn and Cu as compared to either control untreated or cisplatin treated 208 aroups.

209 Table 4: Effects of cisplatin administration and/ or radiation exposure on levels of Fe. Zn and Cu in testis tissue 24 hours nost radiation exposure (n-6)

210

post radiation exposure (<i>n</i> =6)					
	Treatment X ⁻ ± SD	Control group	Cis. Groug	IRR group	Cis. & IRR group
_	Fe (µg/g fresh tissue) X [∼] <u>+</u> SD	97.91±16.9	69.61±4.6*	87.09±6.4	96.38±21.2 ^(#)
	Zn (µg/g fresh tissue) X⁻ ± SD Cu	128.8± 23.6	91.57±6.1*	106.6±13.1	116.7±21.3
	(µg/g fresh tissue) X⁻ ± SD	1.885±0.39	1.462±0.12*	1.603±0.26	1.603±0.17

211 Data are presented as mean (± SD). *Significantly different from the control group (P<0.05). (#)Significantly different from the Cis. 212 group (P<0.05). IRR: Low radiation dose of 0.5 Gy gamma rays, Cis.: cisplatin administration.

213 3.3.2. Low dose of radiation (0.5 Gy) and its effect on the testis tissue after cisplatin treatment:

214 Exposing cisplatin treated animals to low dose of gamma radiation (0.5 Gy) caused a non- significant decrease in serum 215 FSH activity as compared to the normal control level, which means a significant decrease (-24%, P<0.05) as compared to 216 the cisplatin treated animals only (Fig. 2). In addition, the effect of whole body gamma radiation (0.5 Gy) on the animals 217 treated with cisplatin only caused a significant increase in testis GSH content comparing to the cisplatin treated group.

This increase was calculated 42% (Table 2) haunt with a non significant change when compared to the normal untreated group, while the concentration of P450 showed no significant change comparing to normal control levels accompanied by a significant increase (68%, *P*<0.05) with regards to cisplatin treated group.

In case of trace metals concentration, testis Fe, Zn as well as Cu level was estimated in the group of animals exposing to low dose of gamma radiation (0.5 Gy) after cisplatin injection as in table (3). A significant change in the level of testisFe, Zn and Cu in this group was recorded when compared with either normal untreated control group or cisplatin treated one.

4. DISCUSSION

Cisplatin is the most widely used antitumor drug especially in the treatment for testicular cancer, but its usage is limited by toxic effects on the reproductive system [32]. Testicular damage induced by cisplatin treatment was characterized by significant decreases in plasma testosterone level [33] that may be due to the increase in FSH level as in the current work, since according to Sasson and his colleagues the gonadal failure caused by cisplatin treatment, leads to high levels of FSH and LH [34].

230 Once cisplatin has been administered in the body, it rapidly diffuses into tissues and is highly bound to plasma albumin 231 and other protein [35]. This may explain why cisplatin caused a decrease in serum albumin in the present work. In 232 addition, the decrease in both serum albumin concentration as well as butyryle cholinesterase with the increase in serum 233 GPT activities are further evidence that anti-tumoral treatment causes liver damage [36]. According to the observation of 234 Cepeda and his colleagues, there is a direct connection between the cellular concentrations of copper and platinum 235 recommended an active transport for cisplatin through copper transporter, which reduce the uptake of each other that 236 indicated as a significant decrease in testicular copper levels together with Zn and iron that may be due to cisplatin 237 treatment induced oxidative stress in testis [2]. Consequently, increase in lipid peroxidation (LPO) and depletion of 238 enzymes such as superoxide dismutase following cisplatin treatment in testis and liver clearly demonstrated failure of 239 their antioxidant defence system [33]. It may be noted that previous investigators reported the reduction of GSH levels 240 leads to elevation of LPO [37 & 38]. Therefore, depletion of GSH as in the present results might be inducing oxidative 241 stress by increasing the free radical generation leading to cell death in both tested organs.

242 Cytochrome p450 is the catalyst enzymes that are essential for the metabolism of many medications. Suppression of 243 P450 may be due to the consequence of inflammatory processes and can result in increased clinical toxicity of drugs with 244 a low therapeutic index [39]. Down regulation of testicular cytochrome P450 reported by Waxman and Change and 245 Masubuchi and his colleagues and also indicated in the present results [40 & 41]. However, exposing to low radiation 246 dose attenuated the level of P450 after cisplatin treatments. In addition, evidence reported by Oetari and his colleagues 247 indicates inactivation of glutathione- S- transferase accompanied by glutathione depletion and inhibition of cytochrome 248 p450 in liver [42]. Interestingly, the cytochrome p450 and GSH content in both liver and testis showed a significant 249 inhibition than the control group in our current study. Moreover, the active site of cytochrome p450 contain iron heme 250 center [43], so as one could explain the decrease in both cytochrome p450 and iron in testis as in present work.

251 Cisplatin augments the antitumor effect of a cytotoxic T-lymphocyte-mediated immunotherapy strategy, resulting in a 252 higher cure rate. This effect is associated with the enhanced ability of cytotoxic T lymphocytes to lyse tumor cells [44]. It 253 seems that functional activity of lymphocytes decreased at the stage of well-developed tumor, which promoted inhibition 254 of the lymphocyte defense properties. Cisplatin did not modify the structure and functions of lymphocytes and presumably 255 improved their energy status [45]. So to overcome the above problems and as the evidence of Murphy and Morton [22], 256 exposing to low radiation dose can be used as a synergistic agent with cisplatin for cancer treatment since low radiation 257 dose administration to entire body increased the action of the protective process in living organism including the 258 overproduction lymphocytes that significantly prevented or impaired tumor growth. Besides, an interesting observation 259 remarked that sign of glutathione (GSH) protects against cisplatin cytotoxicity [46]. Of note is that the GSH administration 260 achieved a superior response rate despite having a larger average tumor burden during chemotherapy [47]. According to 261 current study animals exposed to low radiation dose alone (0.5 Gy) showed a significant increase in GSH content in both 262 liver and testis tissue, which may explain the antioxidant effects of low radiation dose against cisplatin induced oxidative 263 stress. These antioxidants did not interfere with chemotherapeutic effects - and mitigated cancer treatment toxicity [48].

264

5. CONCLUSION

In conclusion, the obtainable results proved that low radiation dose have the existence as an antioxidant and antitumor agents which may be useful to use as a synergistic agents with the chemotherapeutic drug or even in case of tumors chemo-radiotherapy. Further studies should be needed to address this issue in different biochemical views.

270 **CONSENT**

Not applicable.

272 ETHICAL APPROVAL

All authors hereby declare that "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985) were
 followed, as well as specific national laws where applicable. All experiments have been examined and approved by the
 appropriate ethics committee.

276 COMPETING INTEREST

- 277 Authors have declared that no competing interests exist.
- 278

279 6. REFERENCES

- 280 1. Giaccone, G. Clinical perspectives on platinum resistance. Drugs. 2000; 59 (Suppl 4): 9–17.
- Cepeda, V, Miguel, AF, Castilla, J, Alonso, C, Quevedo, C, and Pérez, JM. Biochemical Mechanisms of Cisplatin Cytotoxicity, Anti-Cancer Agents in Medicinal Chemistry. 2007; 7: 3-18
- Chirino, YI, Pedraza- Chaverri, J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity.
 Exp Toxicol Pathol. 2009; 61(3):223-42. doi: 10.1016/j.etp.2008.09.003. Epub 2008 Nov 4.
- Hassan, I, Chibber, S., Khan, AA, Naseem, I. Riboflavin Ameliorates Cisplatin Induced Toxicities under Photoillumination. PLoS ONE. 2012; 7(5): e36273.
- 287 5. González, VM, Fuertes, MA, Alonso, C, Pérez, JM. Mol. Pharmacol. 2001; 59: 657.
- Sadowitz, PD, Hubbard, BA, Dabrowiak, JC, Goodisman, J, Tacka, KA, Aktas, MK, Cunningham, MJ, Dubowy,
 RL, Souid, AK. Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol
 drugs. Drug Metab. Dispos. 2002; 30: 183–190.
- Coia, L, Won, M, Lanciano, R, Marcial, VA, Martz, M, Hanks, G. The patterns of care outcome study for cancer
 of the uterine cancer: Results of the second national practice survey. Cancer. 1990; 66: 2451-2456.
- 8. Morri, y, Shara, H, Shima, H, Shimada, K, Arima, M, Ikoma, F. Combined cisplatin and radiation therapy in patients with invasive bladder cancer. International Urology and Nephrology. 1990; 22(4): 337- 343.
- Wodinsky, I, Swiniarki, J, Kensler, CJ, Venditti, JM. Combination radiotherapy and chemotherapy for P388
 lymphocytic leukemia in vivo. Cancer Chemother Rep. 1974; 4: 73.
- Morris, CR, Blackwell, LH, Loveless, VS. Antileukemic of combination of radiation and malanats (1,2 diamininocyclohexane) platinum II (NSC. 224964) J Med. 1977; 8: 254 (1977)
- 299
 11. Omura, GA. (1996) Chemotherapy for stage IVB or recurrent cancer of the uterine cervix. Journal of the National Cancer Institute. 1996; 21:123–6.
- Wallner, KE, Li, GC. Effect of cisplatin resistance on cellular radiation response. Int J Radiat Onco Biol Phys.
 1987; 13:587–91.

- Perez, CA, Grigsby, PW, Castro, Vita, H, Lockett, MA. (1995) Carcinoma of the uterine cervix. I. Impact of prolongation of treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Onco Biol Phys. 32:1275–88.
- 306 14. Green, JA, Kirwan, JM, Tierney, JF, *et al.* Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001; 358: 781-6.
- Ishizuka, M., Fujimoto, Y, Itoh, Y, Kitagawa, K, Sano, M, Miyagawa, Y, Ando, A, Hiramatsu, M, Hirasawa, N, Ishihara, S, Nakashima, T, Yamada, K. Relationship between hematotoxicity and serum albumin level in the treatment of head and neck cancers with concurrent chemo-radiotherapy using cisplatin. Jpn. J. Oncol. 2011; 41(8): 973- 979.
- Nogami, M, Huang, JT, James, SJ. Mice chronically exposed to low dose ionizing radiation possess
 splenocytes with increased levels of HSP70 mRNA, HSC72 and HSP70 and with an increased capacity to
 proliferate. Int J Radiat Biol. 1993; 63:775–783.
- Kojima, S, Nakayama, K, Ishida, H. Low Dose γ-Rays Activate Immune Functions via Induction of Glutathione
 and Delay Tumor Growth. J Radiat Res. 2004; 45 (1): 33-39. doi: 10.1269/jrr.45.33
- Feinendegen, LF. Evidence for beneficial low level radiation effects and radiation hormesis. Brit J Radiol. 2005;
 78: 3-7. doi:10.1259/bjr/63353075
- Gharib, OA, Abd Ellatif, UA, Abdellah, NM, Mohammad, MA. Radio-protective response on the environmental pollutant induced oxidative stress. Adv Bioscie Biotech. 2012; 3: 989-996.
- 321 20. Kopp, AH, Eifel, PJ. Chemo-radiotherapy for cervical in 2010. Curr Oncol Rep. 2011; 13:77-85.
- 322 21. Turner, J.E. (1995). Atoms radiation and radiation protection (2nd Edition), John Willy & Sons, inc., New York.
- Murphy JB, Morton JJ. The effect of roentgen rays on the rate of growth of spontaneous tumors in mice. J Exper Med. 1915; 22 (6):800–803.
 Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2125377/pdf/800.pdf. [PMC free article]
- Barcellos-Hoff, MH, Park, C, Wright, EG. Radiation and the microenvironment tumorigenesis and therapy. Nat
 Rev Cancer. 2005; 5: 867–875.
- Máthé, A, Komka, K, Forczig, M, Szabó, D, Anderlik, P, Rozgonyi, F. The effect of different doses of cisplatin
 on the pharmacokinetic parameters of cefepime in mice. Lab Anim. 2006; 40:296–300
- Munshaw, S, Hwang, HS, Torbenson, M, Quinn, J, Hansen, KD, Astemborski, J, Mehta, SH, Ray, SC, Thomas,
 DL, Balagopal, A. Laser captured hepatocytes show association of butyrylcholinesterase gene loss and fibrosis
 progression in hepatitis C-infected drug users. Hepatology. 2012; 56(2):544-54. doi: 10.1002/hep.25655.
- 26. Doumas, BT, Watson, WA, Biggs, HG. Albumin standards and the measurement of serum albumin with
 bromcresol green. Clin Chim Acta. 1971; 31: 87-95
- 335 27. Beutler, E. Red Cell Metabolism: A Manual of Biochemical Methods, Grune and Stratton, New York. 1971.
- 336 28. Nerurkar, PV, Park, SS, Thomas, PE, Nims, RW, Lubet, RA. Methoxyresorufin and benzyloxyresorufin:
 337 substrates preferentially metabolized by cytochromes P4501A2 and 2B, respectively, in the rat and mouse.
 338 Biochem Pharmacol. 1993; 46: 933-943.
- 339
 29. IAEA. Elemental analysis of biological materials. Current problem and techniques with special reference to trace elements. International Atomic Energy Agency, IAEA, Vienna. Technical Reports Series. 1980; 379.
- 341
 30. Kingstone, HM, Jassie, L. Introduction to microwave sample preparation. Theory and practice. American
 342 Chemical Socity Professional Reference Book, Washington DC. 1998; 263.

- 343
 31. Gregus, Z, Klaassen, CD. Disposition of metals in rats: A comparative study of fecal urinary and billary excretion and tissue distribution of eighteen metals. Toxicology and Applied Pharmacology. 1986; 85: 24-38. doi:10.1016/0041-008X(86)90384-4
- 346
 32. Ciftci, O, Beytur, A, Cakir, O, Gurbuz, N, Vardi, N. Comparison of Reproductive Toxicity Caused by Cisplatin and Novel Platinum-N-Heterocyclic Carbene Complex in Male Rats. Basic & Clinical Pharmacology & Toxicology. 2011; 109: 328–333.
- 350
 33. Fahmy, HA, Abd El-Azime, ASh, Gharib, OA. Possible Ameliorative Role of Low Dose of Radiation Against Cisplatin Induced Oxidative Stress and Tissue Damage in Male Rats. Euro J Biol Medi Sci Resh. 2013; 1(4): 10-18.
- 353 34. Sasson, R, Dantes, A, Tajima, K, Amsterdam, A. Novel genes modulated by FSH in normal and immortalized 354 FSH-responsive cells: new insights into the mechanism of FSH action. FASEB J. 2003; 17(10):1256-66.
- 356 35. Judson, I, Kelland, LR. New developments and approaches in the platinum arena. 2000; 59: 29.

349

- 357 36. Fasihi, M, Ghodratizadeh, S, Ghodratizadeh, S. Protective Effect of Captopril on Cisplatin Induced 358 Hepatotoxicity in Rat. American-Eurasian. J Toxicol Sci. 2012; 4(3): 131-134.
- 359
 37. El-Maraghy, SA, Gad, MZ, Fahim, AT, Hamdy, M A. Effect of cadmium and aluminum intake on the antioxidant status and lipid peroxidation in rat tissues. 2001; J Biochem Mol Toxicol. 2001; 15(4):207-14.
- 361
 38. Gharib, OA, Ibrahim, NK. Oxidative damage in testes induced by 950 MHz simulating cellular phone. Isotope and Radiat Res. 2010; 42(4), 9 4 1 9 5 3.
- 363 39. Morgan, ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev. 1997;
 29:1129–1188.
- Waxman, DJ, Chang, TKH. Hormonal regulation of liver cytochrome P450 enzymes. In Cytochrome P450:
 Structure, Mechanism, and Biochemistry (2nd edition). Ortiz de Montellano P. R., editor. Plenum Press, New York. 1995; 391–418.
- Masubuchi, Y, Enoki, K, Horie, T. Down-regulation of hepatic cytochrome P450 enzymes in rats with
 trinitrobenzene sulfonic acid-induced colitis Drug Metab Dispos. 2008; 36(3):597-603.
- 42. Oetari, S, Sudibyo, M, Commandeur, JN, Samhoedi, R, Vermeulen, NP. Effects of curcumin on cytochrome
 P450 and glutathione S-transferase activities in rat liver. Biochem Pharmacol. 1996; 12,51(1):39-45.
- 43. Guengerich, FP. "Cytochrome p450 and chemical toxicology". Chem. Res. Toxicol. 2008; 21 (1): 70–83.
- 44. Merritt, RE, Mahtabifard, A, Yamada, RE, Crystal, RG, Korst, RJ. (2003) Cisplatin augments cytotoxic Tlymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer. J Thorac Cardiovasc
 Surg. 2003; 126(5):1609-17.
- Zamay, TN, Kolovskaya, OS, Zamay, GS, Borodina, NA. Effects of Cisplatin on Lymphocyte Structure and
 Functions in Mice with Ehrlich Ascitic Carcinoma. Bull Experi Biol & Medi. 2011; 151 (1): 62-65.
- 46. Lu, y, Kawashima, A, Horri, I, Zhong, L. Effect of BSO and L- cysteine on drug induced cytotoxicity in primary
 cell cultures: drug-, cell type- and species- specific difference. Drug Chem. Toxicol. 2004; 27: 269- 280.
- 380
 47. Schmidinger, M, Budinsky, AC, Wenzel, C, Piribauer, M, Brix, R, Kautzky, M, Oder, W, Locker, GJ, Zielinski,
 381
 382
 383
 47. Schmidinger, M, Budinsky, AC, Wenzel, C, Piribauer, M, Brix, R, Kautzky, M, Oder, W, Locker, GJ, Zielinski,
 384
 385
 386
 47. Schmidinger, M, Budinsky, AC, Wenzel, C, Piribauer, M, Brix, R, Kautzky, M, Oder, W, Locker, GJ, Zielinski,
 385
 386
 387
 388
 388
 388
 388
 388
 388
 388
 47. Schmidinger, M, Budinsky, AC, Wenzel, C, Piribauer, M, Brix, R, Kautzky, M, Oder, W, Locker, GJ, Zielinski,
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388
 388</l

Block, KI, Koch, AC, Mead, MN, Tothy, PK, Newman, RA, Gyllenhaal, C. Impact of antioxidant supplementation
on chemotherapeutic efficacy: A systematic review of the evidence from randomized controlled trials, Cancer
Treatment Reviews. 2007. doi:10.1016/j.ctrv.2007.01.005.